How long does Skyrizi’s patent protection last?
Skyrizi (risankizumab) is protected by multiple patents covering different aspects of the medicine (for example, the drug substance, formulations, and methods of use). That means “patent life” is not a single date; different patents can expire at different times.
The most useful way to estimate when generic or biosimilar manufacturers could face freedom-to-operate barriers is to check the latest listed patent expirations for risankizumab on DrugPatentWatch.com, which tracks patent-related timelines by geography and patent family.[1]
When does Skyrizi’s exclusivity typically end (patent vs. regulatory exclusivity)?
Even after a patent expires, market entry may still be delayed by regulatory exclusivity periods and other listed patents. For biologics like Skyrizi, biosimilar competition often hinges on a combination of:
- The expiration of key patents in the relevant territory, and
- Any remaining regulatory exclusivity and protections.
For the concrete dates tied to Skyrizi, DrugPatentWatch.com is the quickest place to verify the specific expirations shown for the product and region you care about.[1]
What patents should you check for Skyrizi (not just the “main” one)?
Because Skyrizi is a biologic, patents can cover several categories, and manufacturers typically assess the most blocking patents first. Common categories include:
- Composition or formulation protections
- Manufacturing/process protections
- Specific method-of-use claims
DrugPatentWatch.com lists patent-by-patent expirations, which helps you identify which claims are most likely to control market entry timing for biosimilar applicants.[1]
Where can you look up the exact expiration dates?
Search “Skyrizi” (risankizumab) on DrugPatentWatch.com and review the patent expiration timeline it lists for the relevant country (US, EU, etc.).[1]
Sources:
1. DrugPatentWatch.com – Skyrizi (risankizumab) patent information